IMPORTANT SAFETY INFORMATION FOR TRIPTODUR
INDICATION
TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central
precocious puberty (CPP).
IMPORTANT SAFETY INFORMATION
Do not use TRIPTODUR in:
- Those allergic to gonadotropin releasing hormone (GnRH), GnRH agonist medicines, or any ingredients in
TRIPTODUR.
- children under 2 years of age
- women who are or may become pregnant
Tell your child’s healthcare provider if any of the above conditions apply to your child.
It is important to stick to the dosing schedule (one injection every 24 weeks) in order for the drug to work.
Do not miss or delay a scheduled dose.
Some people taking gonadotropin releasing hormone (GnRH) agonists like TRIPTODUR have had new or worsened
mental (psychiatric) problems. Mental (psychiatric) problems may include emotional symptoms such as crying,
irritability, restlessness (impatience), anger, or acting aggressive. Call your child’s doctor right away if
your child has any new or worsening emotional symptoms while taking TRIPTODUR.
Some people taking GnRH agonists like TRIPTODUR have had seizures. The risk of seizures may be higher in
people who have a history of seizures, have a history of epilepsy, have a history of brain or brain vessel
(cerebrovascular) problems or tumors, are taking a medicine that has been connected with seizures such as
bupropion or selective serotonin reuptake inhibitors (SSRIs). Seizures have also happened in people who have
not had any of these problems. Call your child’s doctor right away if your child has a seizure while taking
TRIPTODUR.
Some people taking triptorelin, the active ingredient in TRIPTODUR, have had serious allergic reactions. Call
your child’s doctor or get emergency medical help right away if your child gets any of the following
symptoms of a serious allergic reaction: skin rashes, redness, or swelling, severe itching, hives, trouble
breathing or swallowing, fast heartbeat, sweating, throat tightness, hoarseness, swelling of face, mouth,
and tongue, dizziness or fainting.
The most common side effects of TRIPTODUR include injection site reactions, menstrual (vaginal) bleeding, hot
flush, headache, cough, and infections (bronchitis, gastroenteritis, influenza, nasopharyngitis, otitis
externa, pharyngitis, sinusitis, and upper respiratory tract infection). These are not all the possible side
effects of TRIPTODUR. Tell your child’s healthcare provider if they have any side effect that bothers them
or that does not go away.
In the first few weeks after your child receives their first TRIPTODUR injection or after additional
injections, TRIPTODUR can cause a brief increase in some hormones. During this time you may notice
more signs of puberty in your child, including vaginal bleeding. Call your child’s doctor if signs of
puberty continue after 2 months of receiving TRIPTODUR.
Reports of pseudotumor cerebri (idiopathic intracranial hypertension) have been observed in pediatric
patients receiving GnRH agonists, including triptorelin. Patients and caregivers should contact their
healthcare provider if the patient develops any of following symptoms of pseudotumor cerebri, including
headache, and vision issues such as blurred vision, double vision, loss of vision, pain behind the eye or
pain with eye movement, ringing in the ears, dizziness, and nausea.
These are not all the possible side effects of TRIPTODUR. Call your doctor for medical advice about side
effects.
To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at
1-800-461-7449, or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch
The Important Safety Information does not include all the information needed to use TRIPTODUR safely
and effectively. For additional safety information, please consult the full Prescribing Information for
TRIPTODUR.